Document:

EX-10.10

 Exhibit 10.10 
 THIS RELATIONSHIP AGREEMENT (this “Agreement”) is made on
                     2012 by and between Intrexon Corporation, incorporated in Virginia, USA, with offices at
[            ] (“Intrexon”), and AquaBounty Technologies, Inc., incorporated in Delaware, USA, with offices atx 935 Main Street, Waltham, Mass 02451, USA (the
“Company”). 
 RECITALS 
  

	(A)	 	On 31 October 2012, Intrexon agreed to acquire shares constituting 47.56% of the current issued share capital of AquaBounty from Linnaeus Capital Partners B.V. and Tethys
Ocean B.V., which acquisition was completed on 16 November 2012 with Intrexon becoming the owner of such shares. 

  

	(B)	 	In accordance with the Company’s Certificate of Incorporation, Intrexon intends to make a conditional cash offer for any and all shares of common stock of AquaBounty not
already owned by Intrexon (the “Mandatory Offer”). 

  

	(C)	 	The parties to this Agreement wish to record the current and future basis of Intrexon’s relationship with the Company as a major shareholder. 

OPERATIVE PROVISIONS 
  

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	 	In this Agreement the following words and expressions shall have the following meanings unless they are inconsistent with the context: 

“Affiliate” means, as to any person, any other person or entity that, directly or indirectly through one or more intermediaries,
controls, or is controlled by such person; 
 “Board” means the board of directors of the Company from time to time;

 “Business Day” means any day (other than Saturday or Sunday) on which clearing banks are open for a full range of
banking transactions in both London and New York City; 
 “Closing Date” means the date on which the Mandatory Offer
becomes or is declared unconditional in all respects or lapses or is withdrawn in accordance with its terms; 
 “Confidential
Information” means all information which is not publicly known, and which is used in or otherwise relates to the Company’s business, customers, or financial or other affairs, including, without limitation, information relating to:

  

	 	(a)	 	trade secrets, know-how, ideas, computer systems and computer software; 

  

	 	(b)	 	future projects, business development or planning, commercial relationships and negotiations; and 

 

	 	(c)	 	the marketing of goods or services including customer names and lists, sales targets and statistics; 

“Director” means a director of the Company from time to time; 

“First Annual Meeting” has the meaning given in clause 2.1. 

“Intrexon Director” has the meaning given in clause 2.5; 

 “Intrexon Nominee” has the meaning given in clause 2.2(a); 

“Intrexon Representative” has the meaning given in clause 2.5; and 

“Mandatory Offer” has the meaning given in Recital (B). 

 

	1.2	 	In this Agreement: 

  

	 	(a)	 	references to clauses and parties are, unless otherwise stated, to the clauses of and the parties to this Agreement; 

 

	 	(b)	 	words importing the singular include the plural and vice versa, words importing a gender include every gender and references to persons include bodies corporate or
unincorporated; 

  

	 	(c)	 	the headings to the clauses are for convenience only and shall not affect the construction or interpretation of this Agreement; and 

 

	 	(d)	 	references to any statute or statutory provision include, unless the context otherwise requires, a reference to the statute or statutory provision as modified, replaced or
reenacted and in force from time to time prior to the date hereof and any subordinate legislation made under the relevant statute or statutory provision (as so modified, replaced or re-enacted) in force prior to the date hereof.

  

	2.	 	INTREXON NOMINEE; INTREXON REPRESENTATIVE 

 

	2.1	 	As soon as practicable after the Closing Date, and in any case no later than the later of (x) ten (10) Business Days after the Closing Date and (y) thirty
(30) days after the date on which Intrexon submits names to the Company’s Nominated Advisor, the Company shall take or cause to be taken all necessary actions to (A) increase the size of the Board from three (3) to six
(6) directors and (B) appoint three (3) nominees of Intrexon (each an “Intrexon Nominee” and together the “Intrexon Nominees”) as directors of the Company with terms expiring at the next annual
meeting of the shareholders of the Company occurring after the date of such appointment (the “First Annual Meeting”); provided, however that if as a result of the Mandatory Offer Intrexon becomes the beneficial owner of greater than
50% of the outstanding common stock of the Company, the Company shall take or cause to be taken all necessary actions to (A) increase the size of the Board from three (3) to seven (7) directors and (B) appoint four
(4) Intrexon Nominees as directors of the Company with terms expiring at the First Annual Meeting. Intrexon shall have the right to nominate each Intrexon Nominee from among the officers and directors of Intrexon (or any such other persons with
at least similar stature and experience, in the reasonable judgment of the Board), provided, however, that for so long as the Company is listed on the AIM Market of the London Stock Exchange that (i) Intrexon acknowledges the obligation of the
Company’s Nominated Advisor under the AIM Rules to undertake due diligence on any prospective Intrexon Nominee and agrees to cooperate with the Nominated Advisor’s reasonable enquiries and (ii) Intrexon will not exercise its voting
rights in a manner designed to prevent the Company from having on the Board at all times two directors who are independent of Intrexon and the Company. 

  

	2.2	 	The Company agrees that so long as (i) this Agreement continues in full force and effect and has not been terminated pursuant to clause 6 (Duration) and
(ii) Intrexon itself or together with its Affiliates control 25% or more of the voting rights exercisable at meetings of the shareholders of the Company, the Company will procure that the Board will, in advance of the First Annual Meeting and
thereafter in advance of each annual meeting of the shareholders of the Company: 

	 	(a)	 	nominate such number of Intrexon Nominees as may be designated by Intrexon for election as directors of the Company at each forthcoming annual meeting of shareholders of the
Company occurring after the date of such nomination so that Intrexon shall have representation on the Board proportional to Intrexon’s percentage shareholding in the capital of the Company rounded up to the nearest whole person in the event
that Intrexon’s representation on the Board would not as a result constitute at least a majority of the directors on the Board and rounded arithmetically to the nearest whole person in the event that Intrexon’s representation on the Board
would as a result constitute a majority of the Board; provided, that each such nomination shall not include any individual whose membership on the Board would be a violation of law and shall be in accordance with the Bylaws of the Company then in
effect; and provided, further, that should the Board determine that any such designee of Intrexon is inappropriate, consistent with the standards set forth in this clause 2.2(a), Intrexon shall be entitled to designate, as a substitute, an
additional individual for election as a director of the Company that shall meet the standards set forth in this clause 2.2(a) and such individual shall be deemed an Intrexon Nominee; and 

 

	 	(b)	 	recommend that the shareholders of the Company vote to elect each such Intrexon Nominee as a director of the Company at the next annual meeting of shareholders of the Company
occurring after the date of such nomination. 

  

	2.3	 	In the event that an Intrexon Nominee, nominated for election to the Board in accordance with clause 2.2(a), fails to be elected to the Board by the shareholders at the
applicable annual meeting, the Company shall, as an ongoing obligation, procure that the Board take such steps as are permitted by the Bylaws and any applicable law to appoint such Intrexon Nominee to fill any vacancy. 

 

	2.4	 	If a member of the Board that has been designated by Intrexon resigns or is removed from the Board and Intrexon indicates that it does not wish to designate a nominee to fill the
vacancy or fails to nominate a designee that meets the standards set forth in clause 2.2(a) to replace such individual within ten (10) Business Days following receipt of notice of such resignation or removal, the Company will take or cause to
be taken all necessary actions to reduce the size of the Board so that there is no vacancy as a result thereof and then to promptly increase the size of the Board to create a vacancy at such time as Intrexon indicates that it wishes to designate a
nominee to fill the vacancy that meets the standards set forth in clause 2.2(a). Upon termination of this Agreement pursuant to clause 6 (Duration), Intrexon shall, upon the written request of the Board, cause such member(s) of the Board that
have been designated by Intrexon to resign from the Board, effective immediately. 

  

	2.5	 	Intrexon shall be entitled to, and the Company shall procure that it may, send a representative (an “Intrexon Representative”) to attend and speak at, but not to
vote at, any meetings of the board of subsidiary of the Company if at such time it has no Intrexon-appointed director serving on the board of directors of that subsidiary (any such Intrexon-appointed director, an “Intrexon
Director”). 

  

	2.6	 	The Company agrees that, for so long as there is an Intrexon Nominee on the Board, it will procure director insurance of a type and at a level of coverage that is customary for
members of a board of directors of a publicly listed company and reasonably acceptable to Intrexon. 

	2.7	 	The Company agrees that, for so long as there is an Intrexon Nominee on the Board, it will enter into a customary form of indemnification agreement with each Intrexon Nominee in
a form reasonably acceptable to Intrexon. 

  

	3.	 	REPORTING COMPLIANCE. 

  

	3.1	 	For so long as Intrexon itself or together with its Affiliates controls 10% or more of the voting rights exercisable at meetings of the shareholders of the Company, for any time
period for which Intrexon has notified AquaBounty that Intrexon has reasonably concluded, after consultation with its outside advisors, that Intrexon is required to consolidate or include AquaBounty’s financial statements with its own,
AquaBounty shall comply with the following additional obligations: 

  

	 	(a)	 	AquaBounty shall maintain at its principal place of business or, upon notice to Intrexon, at such other place as AquaBounty shall determine: 

 

	 	(i)	 	a copy of AquaBounty’s Certificate of Incorporation or organizational document and all amendments thereto, together with executed copies of any powers of attorney pursuant
to which any amendment has been executed; 

  

	 	(ii)	 	a copy of this Agreement; 

  

	 	(iii)	 	a copy of AquaBounty’s federal, state, and local income tax returns and reports, if any; and 

 

	 	(iv)	 	minutes of meetings of AquaBounty’s board of directors and shareholders or actions by written consent in lieu thereof, redacted as necessary by AquaBounty to exclude any
sensitive or confidential information that Intrexon, by operation of law or contractual stipulation, is not permitted to receive. 

  

	 	(b)	 	AquaBounty shall keep its books and records consistent with United States generally accepted accounting principles (US GAAP). 

 

	 	(c)	 	Intrexon at its own expense and upon reasonable notice, may examine any information it may reasonably request (including, to the extent AquaBounty has the right to provide such,
the work papers of AquaBounty’s internal and independent auditors) and make copies of and abstracts from the financial and operating records and books of account of AquaBounty, and discuss the affairs, finances and accounts of AquaBounty with
AquaBounty and independent auditors of AquaBounty, all at such reasonable times and as often as Intrexon or any agents or representatives of Intrexon may reasonably request. The rights granted pursuant to this clause 3.1(c) are expressly subject to
compliance by Intrexon with the safety, security and confidentiality procedures and guidelines of AquaBounty, as such procedures and guidelines may be established from time to time. 

 

	 	(d)	 	Unless waived by Intrexon, in its sole discretion, as soon as available but no later than ninety (90) days after the end of each fiscal year, AquaBounty shall cause to be
prepared and Intrexon to be furnished with an audited balance sheet as of the last day of such fiscal year and an audited income statement, a statement of stockholders’ equity and statement of cash flows for AquaBounty for such fiscal year and
notes associated with each, in each case prepared in accordance with US GAAP, together with a report of AquaBounty’s independent auditor that such statements have been prepared in accordance with US GAAP and present fairly, in all
material respects, the financial position, results of operations and cash flows of AquaBounty. 

	 	(e)	 	As soon as available but no later than forty five (45) days after the end of each calendar quarter, AquaBounty shall furnish the following to Intrexon an unaudited balance
sheet as of the last day of such period, and an unaudited income statement, a statement of cash flows and a statement of stockholders’ equity for AquaBounty for such period, in each case prepared in accordance with US GAAP.

  

	 	(f)	 	As requested by Intrexon on no more than a quarterly basis, a certificate, executed by the Chief Executive Officer or Chief Financial Officer of AquaBounty, certifying on behalf
of AquaBounty the following: 

  

	 	(i)	 	AquaBounty maintains accurate books and records reflecting its assets and liabilities and maintains proper and adequate internal accounting controls that provide assurance that
(1) transactions are executed with management’s authorization; (2) transactions are recorded as necessary to permit preparation of the consolidated financial statements of AquaBounty and to maintain accountability for
AquaBounty’s consolidated assets; (3) access to the assets of AquaBounty is permitted only in accordance with management’s authorization; (4) the reporting of assets of AquaBounty is compared with existing assets at regular
intervals; and (5) accounts, notes and other receivables and inventory are recorded accurately, and proper and adequate procedures are implemented to effect the collection of accounts, notes and other receivables on a current and timely basis.

  

	 	(ii)	 	under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; any such controls and procedures are adequate to ensure that all
material information concerning AquaBounty is made known on a timely basis to those individuals responsible for the preparation of any filings that may be required to be made by Intrexon with the SEC and other public disclosure documents.

  

	 	(iii)	 	AquaBounty shall promptly prepare and furnish to Intrexon any information, whether written or oral, requested by Intrexon that is reasonably necessary for purposes of
Intrexon’s ongoing compliance with applicable law. 

  

	3.2	 	The parties agree that the delivery deadlines in clause 3.1 will be modified to the extent necessary to ensure that such deliverables are provided by AquaBounty no less than
thirty (30) days prior to the date necessary for Intrexon to meet any disclosure obligation under rules or regulations to which Intrexon may be or become subject from time to time. Intrexon will provide AquaBounty with notice as promptly as
practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines under this clause 3. 

  

	4.	 	CONFIDENTIALITY 

  

	4.1	 	 The parties acknowledge the existence and continuing effect of the Mutual Confidentiality Agreement effective January 13, 2012 between Intrexon and the
Company, as amended June 25, 2012 and as further amended by this Section 4.1 (the “Mutual Confidentiality Agreement”). The first section of Section 3 of the Mutual Confidentiality Agreement is hereby replaced in its entirety
with the following “The disclosure period of this Agreement shall expire on the date that the Relationship Agreement dated [    ], 2012 between Intrexon and

	 	 
AquaBounty Technologies terminates (the “Disclosure Period”), unless such Disclosure Period is extended by the agreement of the parties in writing.” The definition of
“Confidential Information” in Section 1 of the Mutual Confidentiality Agreement is hereby amended to replace the period at the end of such definition with the following: “; provided, however, that Confidential Information shall
not include any such information that Intrexon can demonstrate was developed by Intrexon independently of and without reference to any Confidential Information or became known to Intrexon (independently of disclosure by the Company) on a
non-confidential basis from a third party lawfully possessing and entitled to disclose such information.”. 

  

	4.2	 	For the avoidance of doubt, information shared by or on behalf of the Company with an Intrexon Nominee is deemed to be shared with such individual in his or her capacity as an
Intrexon Nominee and not in his or her capacity as an employee, consultant or agent of Intrexon; provided, however, that each Intrexon Nominee shall be entitled to disclose to Intrexon such information concerning the Company as he or she thinks fit,
to the extent permitted by applicable law, and that information that constitutes Confidential Information under the Confidentiality Agreement that is disclosed to Intrexon shall be subject to the terms of the Confidentiality Agreement.

  

	5.	 	CAPACITY AND LIABILITY 

 Each party warrants and represents to the other that it has the power to enter into this Agreement and to exercise its rights and to perform its obligations hereunder and all corporate and other action required to
authorise its execution of this Agreement and its performance of its obligations hereunder has been duly taken. 
  

	6.	 	DURATION 

 This
Agreement will continue in full force and effect until Intrexon itself or together with its Affiliates ceases to control 10% or more of the voting rights exercisable at meetings of the shareholders of the Company, save that the provisions of clauses
4 (Confidentiality), 10 (Notices) and 13 (Governing Law) shall survive termination of this Agreement. 
  

	7.	 	ENTIRE AGREEMENT 

 This Agreement (together with any documents referred to herein) constitutes the entire agreement between the parties hereto in connection with the subject matter of this Agreement. 

 

	8.	 	WAIVERS AND AMENDMENTS 

 

	8.1	 	No waiver of any term, provision or condition of this Agreement shall be effective unless such waiver is evidenced in writing and signed by the waiving party.

  

	8.2	 	No omission or delay on the part of any party to this Agreement in exercising any right, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any
single or partial exercise of any such right, power or privilege preclude any other or further exercise thereof or of any other right, power or privilege. The rights and remedies in this Agreement are cumulative with and not exclusive of any rights
or remedies provided by law. 

  

	8.3	 	No amendment or modification to this Agreement shall be effective unless in writing and signed by all parties. 

	9.	 	ASSIGNMENT 

 No party to this Agreement may assign, transfer or charge all or any of the other parties’ obligations nor any of its rights or benefits arising under this Agreement without the prior written consent of the
other party; except that Intrexon may assign, transfer or charge all or any of its obligations, rights and benefits arising under this Agreement without the prior written consent of the Company to (i) an Affiliate of Intrexon or (ii) to
the transferee in the event Intrexon sells, conveys, disposes or otherwise transfers all of its shares of AquaBounty common stock. 
  

	10.	 	NOTICES 

 Any
demand, notice or other communication in connection with this Agreement will be in writing and will, if otherwise given or made in accordance with this clause 10, be deemed to have been duly given or made as follows: 

 

	 	(a)	 	if sent by prepaid first class post to the recipient at its registered office (or such other address as may be notified to the other parties by a recipient in writing), on the
second Business Day after the date of posting; 

  

	 	(b)	 	if sent by air mail to the recipient at its registered office (or such other address as may be notified to the other parties by a recipient in writing), on the sixth Business Day
after the date of posting; or 

  

	 	(c)	 	if delivered by hand, upon delivery to the recipient at its registered office (or such other address as may be notified to the other parties by a recipient in writing),

 provided that, if it is delivered by hand or sent by facsimile on a day which is not a Business Day or after 4 p.m. (at
the location of the recipient) on a Business Day, it will instead be deemed given or made on the next Business Day. 
  

	11.	 	INVALIDITY 

 If
at any time any one or more of the provisions of this Agreement is or becomes invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions shall not be in any way affected or
impaired thereby. 
  

	12.	 	COUNTERPARTS 

This Agreement may be executed in any number of counterparts and by the parties on separate counterparts, each of which when so executed and
delivered shall be an original, but all the counterparts shall together constitute one and the same instrument. 
  

	13.	 	GOVERNING LAW 

 All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware,
without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto
or its respective affiliates, employees or agents) shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and 

 
hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such New York Court, or that such Proceeding has been
commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. For the purposes of this Agreement, “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an
investigation or partial proceeding, such as a deposition), whether commenced or threatened. 
 [Signatures Appear on the Following Page]

 THIS AGREEMENT is executed and delivered on the date stated at the
beginning of this Agreement. 
  

			
	Intrexon Corporation
		
	 By:
	 	 /s/ Thomas R.
Kasser

			
	 Name:
	 	 Thomas R. Kasser

			
	 Title:
	 	 President, Animal Science Division

SVP, Intrexon Corporation

  

			
	
	AquaBounty Technologies, Inc.
		
	 By:
	 	 /s/ David A.
Frank

			
	 Name:
	 	 David A. Frank

			
	 Title:
	 	 Chief Financial OfficerEX-10.11

 Exhibit 10.11 
 EXECUTION COPY 
 CONFIDENTIAL 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act
of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the
“Agreement”) is made and entered into effective as of March 29, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with
offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and AMPLIPHI BIOSCIENCES CORPORATION, a Washington corporation having a place of business at 800 E.
Leigh St., Suite 54, Richmond, VA, 23219 (“Ampliphi”). Intrexon and Ampliphi may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 
 WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and
DNA vectors, and the control of peptide expression; and 
 WHEREAS, Ampliphi now desires to become
Intrexon’s exclusive channel collaborator with respect to such technology for the purpose of developing the Bacteriophage Program (as defined herein), and Intrexon is willing to appoint Ampliphi as its exclusive channel collaborator in the
Field (as defined herein, and subject to amendments to the definition as permitted herein) under the terms and conditions of this Agreement. 
 NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein, the Parties agree as follows: 

ARTICLE 1 

DEFINITIONS 
 As used in this Agreement, the following capitalized terms shall have the following meanings: 
 1.1 “Affiliate” means, with respect to a particular Party, any other person or entity that directly or indirectly controls, is controlled by, or is in common control with such
Party. As used in this Section 1.1, the term “controls” (with correlative meanings for the terms “controlled by” and “under common control with”) means the ownership, directly or indirectly, of more than fifty
percent (50%) of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership of voting securities, by
contract, or otherwise. Notwithstanding the foregoing, Third Security shall be deemed not to be an Affiliate of Intrexon, and neither Party shall be deemed to be an Affiliate of the other Party. In addition, any other person, corporation,
partnership, or other entity that would be an Affiliate of Intrexon solely because it and Intrexon are under common control by Randal J. Kirk or by investment funds managed by Third Security or an affiliate of Third Security shall also be deemed not
to be an Affiliate of Intrexon. 
 1.2 “Ampliphi Indemnitees” has the meaning set forth in
Section 9.1. 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.3 “Ampliphi Product” means any product in the Field that is
created, produced, developed, or identified in whole or in part during the Term through use or practice of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials. 
 1.4 “Ampliphi Program Patent” has the meaning set forth in Section 6.2(b). 
 1.5 “Ampliphi Termination IP” means all Patents or other intellectual property that Ampliphi or any of its Affiliates Controls as of the Effective Date or during the Term that
cover, or is otherwise necessary or useful for, the development, manufacture or Commercialization of a Reverted Product or necessary or useful for Intrexon to operate in the Field. 

1.6 “Applicable Laws” has the meaning set forth in Section 8.2(d)(xii). 

1.7 “Authorizations” has the meaning set forth in Section 8.2(d)(xii). 

1.8 “Bacteriophage Program” has the meaning set forth in Section 2.1(a). 

1.9 “CC” has the meaning set forth in Section 2.2(b). 

1.10 “Channel-Related Program IP” has the meaning set forth in Section 6.1(c). 

1.11 “Claims” has the meaning set forth in Section 9.1. 

1.12 “CMCC” has the meaning set forth in Section 2.2(b). 

1.13 “Committees” has the meaning set forth in Section 2.2(a). 

1.14 “Commercialize” or “Commercialization” means any activities directed to marketing,
promoting, distributing, importing for sale, offering to sell and/or selling Ampliphi Products. 
 1.15
“Commercial Sale” means for a given product and country the sale for value of that product by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (if
necessary) has been obtained for such product in such country. 
 1.16 “Complementary In-Licensed Third Party
IP” has the meaning set forth in Section 3.8(a). 
 1.17 “Confidential Information” means
each Party’s confidential Information, disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties, regardless of whether in oral, written, graphic or electronic form. 

1.18 “Control” means, with respect to Information, a Patent or other intellectual property right, that a Party
owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Party.

  
 2 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.19 “Diligent Efforts” means, with respect to a Party’s
obligation under this Agreement, the level of efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) an Ampliphi Product in a sustained manner, consistent with the efforts and resources a
similarly situated company working in the Field would typically devote to a product of similar potential, taking into account all relevant factors including market potential, profit potential, strategic value and/or proprietary protection,
competition, regulatory risk and manufacturing feasibility, all based on market conditions then prevailing. With respect to a particular task or obligation, Diligent Efforts requires that the applicable Party promptly assign responsibility for such
task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such task or obligation. 
 1.20 “Equity Agreement” has the meaning set forth in Section 5.1. 
 1.21 “Excess Product Liability Costs” has the meaning set forth in Section 9.3. 
 1.22 “Executive Officer” means : (a) the Chief Executive Officer of the applicable Party, or (b) another senior executive officer of such Party who has been duly
appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (i) a Committee dispute, provided that such appointed officer is not a member of the applicable Committee and occupies a position
senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (ii) a dispute described in Section 11.1. 
 1.23 “FDA” has the meaning set forth in Section 8.2(d)(xii). 
 1.24 “Field” means genetically modified bacteriophages using synthetic biology, and the production of bacteriophages using synthetic biology, for bacteriophage-containing human
therapeutics for use (i) in the treatment of bacterial infections associated with acute and chronic wounds, and (ii) the treatment of acute and chronic Pseudomonas aeruginosa lung infections, and (iii) the treatment of
infections of Clostridium difficile. For clarity, the Field does not include the development or production of bacteriophage-containing human therapeutics in which the only bacteriophages included in such therapeutic are (A) not
genetically modified, (B) not developed, selected or produced through the use of Intrexon IP, and (C) not developed or selected without the use of synthetic biology technology (such as in the case of bacteriophages selected through
screening libraries, evolutionary selection, from the environment or other techniques that do not involve recombinant manipulation techniques). 
 1.25 “Field Infringement” has the meaning set forth in Section 6.3(b). 
 1.26 “Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect charges and overheads reasonably allocable to the provision of such good,
product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC and the terms of Sections 4.6 and 4.7 (as appropriate), Intrexon will 

  
 3 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
bill for its internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel directly
involved in the provision of such good, product or service. Intrexon may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the accuracy of its full-time equivalent rate at
least quarterly. Intrexon shall provide Ampliphi with reasonable documentation indicating the basis for any direct and indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 

1.27 “In-Licensed Program IP” has the meaning set forth in Section 3.9(a). 

1.28 “Information” means information, results and data of any type whatsoever, in any tangible or intangible form
whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical,
toxicological and regulatory test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions. 
 1.29 “Infringement” has the meaning set forth in Section 6.3(a). 
 1.30 “Intrexon Channel Technology” means Intrexon’s current and future technology directed towards the design, identification, culturing, and/or production of genetically
modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without limitation the following of Intrexon’s platform areas and capabilities: (1) UltraVector®, (2) LEAPTM, (3) DNA and RNA MOD engineering, (4) protein engineering, (5) transcription control chemistry,
(6) genome engineering, and (7) cell system engineering. 
 1.31 “Intrexon Indemnitees” has
the meaning set forth in Section 9.2. 
 1.32 “Intrexon IP” means the Intrexon Patents and Intrexon
Know-How. 
 1.33 “Intrexon Know-How” means all Information (other than Intrexon Patents) that
(a) is Controlled by Intrexon as of the Effective Date or during the Term and (b) is reasonably required or useful for Ampliphi to conduct the Bacteriophage Program. For the avoidance of doubt, the Intrexon Know-How shall include any
Information (other than Intrexon Patents) in the Channel-Related Program IP. 
 1.34 “Intrexon
Materials” means the genetic code and associated amino acids and gene constructs, in each case that are Controlled by Intrexon, used alone or in combination and such other proprietary reagents and biological materials including but not
limited to plasmid vectors, virus stocks, cells and cell lines, antibodies, and ligand-related chemistry, in each case that are reasonably required or provided to Ampliphi by or on behalf of Intrexon to conduct the Bacteriophage Program. 

1.35 “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date or
during the Term; and (b) are reasonably required or useful for Ampliphi to conduct the Bacteriophage Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

  
 4 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.36 “Intrexon Trademarks” means those trademarks related to the
Intrexon Channel Technology that are established from time to time by Intrexon for use across its channel partnerships or collaborations. 
 1.37 “Inventions” has the meaning set forth in Section 6.1(b). 
 1.38 “IPC” has the meaning set forth in Section 2.2(b). 
 1.39 “JSC” has the meaning set forth in Section 2.2(b). 
 1.40 “Losses” has the meaning set forth in Section 9.1. 
 1.41 “Net Sales” means, with respect to any Ampliphi Product, the net sales of such Ampliphi Product by Ampliphi or an Affiliate of Ampliphi (including without limitation net sales
of Ampliphi Product to a non-Affiliate sublicensee but not including net sales by such non-Affiliate sublicensee), as determined in accordance with US GAAP. 
 1.42 “Patents” means (a) all patents and patent applications (including provisional applications), (b) any substitutions, divisions, continuations, continuations-in-part,
reissues, renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and the like of the foregoing, and (c) any foreign or international equivalents of any of
the foregoing. 
 1.43 “Product-Specific Program Patent” means any issued Intrexon Patent where all the
claims are directed to Inventions that relate solely to Ampliphi Products and where all such claims do not do not relate to applications beyond the Field. In the event of a disagreement between the Parties as to whether a particular Intrexon Patent
is or is not a Product-Specific Program Patent, the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to arbitration pursuant to
Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or
(b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 
 1.44 “Proposed Terms” has the meaning set forth in Section 11.2. 
 1.45 “Prosecuting Party” has the meaning set forth in Section 6.2(c). 
 1.46 “RC” has the meaning set forth in Section 2.2(b). 
 1.47 “Recovery” has the meaning set forth in Section 6.3(f). 

  
 5 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.48 “Reserved ECC Field” means genetically engineered
bacteriophages for, and the production of bacteriophages using synthetic biology for, bacteriophage-containing veterinary therapeutics for use in the treatment of bacterial infections. 

1.49 “Retained Product” has the meaning set forth in Section 10.4(a). 

1.50 “Reverted Product” has the meaning set forth in Section 10.4(c). 

1.51 “SEC” means the United States Securities and Exchange Commission. 

1.52 “Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash consideration,
regardless of whether in the form of upfront payments, milestones, or royalties, actually received by Ampliphi or its Affiliate from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to develop or
Commercialize Ampliphi Products, but excluding: (a) any amounts paid as bona fide reimbursement or prepayment for research and development costs to the extent incurred following such grant; (b) bona fide loans or any payments in
consideration for a grant of equity of Ampliphi to the extent that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing Revenue); and (c) amounts received from
sublicensees in respect of any Ampliphi Product sales that are included in the calculation of royalty payments made to Intrexon under Section 5.4(a). 
 1.53 “Superior Therapy” means a therapy in the Field that, based on the data then available, (a) demonstrably appears to offer either superior efficacy or safety or
significantly lower cost of therapy, as compared with both (i) those therapies that are marketed (either by Ampliphi or others) at such time for the indication or, as evidenced to Intrexon by Ampliphi, have been in human clinical trials for the
same indication by Third Parties, and (ii) those therapies that are being actively developed by Ampliphi for such indication or known by Ampliphi to be or have been in human clinical trials for the same indication by others;
(b) demonstrably appears to represent a substantial improvement over such existing therapies; and (c) has intellectual property protection and a regulatory approval pathway that, in each case, would not present a significant barrier to
commercial development. 
 1.54 “Supplemental In-Licensed Third Party IP” has the meaning set forth in
Section 3.8(a). 
 1.55 “Support Memorandum” has the meaning set forth in Section 11.2.

 1.56 “Technology Access Fee” for the purposes of this Agreement has the meaning as set forth in
Section 5.1. 
 1.57 “Term” has the meaning set forth in Section 10.1. 

1.58 “Territory” means the world. 

  
 6 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 1.59 “Third Party” means any individual or entity other than the
Parties or their respective Affiliates. 
 1.60 “Third Security” means Third Security, LLC. 

1.61 “US GAAP” means generally accepted accounting principles in the United States. 

ARTICLE 2 

SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 

2.1 Scope. 
 (a) Generally. The general purpose of the channel collaboration described in this Agreement will be to use the Intrexon Channel Technology to research, develop and Commercialize Ampliphi Products
for use in the Field (collectively, the “Bacteriophage Program”). As provided below, the JSC shall establish, monitor, and govern projects for the Bacteriophage Program. Either Party may propose potential projects in the Field for
review and consideration by the JSC. 
 (b) Reservation of Bactgeriophage Veterninary Applications. Intrexon and Ampliphi
desire to provide a limited time period for the Parties after the Effecive Date to consider entering into a second exclusive channel collaboration agreement pertaining to certain veterinary applications in the Reserved Field. For a time period of
one year immediately following the Effective Date, neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology or Intrexon Materials available to any Third Party for the purpose of developing or Commercializing products in the
Reserved Field, and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate) the Commercialization of any product for purpose of commercial use or sale in the Reserved Field. For clarity, nothing in the
preceding sentence, however, shall prevent Intrexon from performing general research and development that may be applicable to the Reserved Field. During the one-year period following the Effective Date, Intrexon will not propose, negotiate, or
enter into any collaboration or Commercialization agreement with a Third Party within the Reserved Field, and will, at Ampliphi’s request, enter into negotiations directed toward the execution of a second exlcusive channel collaboration between
the parties, which second exclusive channel collaboration will be directed to the Reserved Field (or a subset of the Reserved Field as mutually agreed by the Parties). The terms of this second exclusive channel collaboration agreement will be
subject to good faith negotiation of the parties with respect to any terms relating to consideration (up-front, milestones, and royalty payments) that will be due to Intrexon, the scope of exclusive field within the Reserved Field, and the relative
rights of the Parties to continue products following any termination, but otherwise will contain similar terms, rights and obligations of the parties as set forth herein. 
 2.2 Committees. 

  
 7 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (a) Generally. The Parties desire to establish several committees (collectively,
“Committees”) to oversee the Bacteriophage Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2.
Each of the Committees shall have the obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 

(b) Formation and Purpose. Promptly following the Effective Date, the Parties shall confer and then create the JSC and the IPC,
and, optionally, create one or more of the other Committees listed in the chart below. Each Committee shall have the purpose indicated in the chart. To the extent that after conferring both Parties agree to not create a Committee (other than the JSC
and the IPC), the creation of such Committee shall be deferred until one Party informs the other Party of its then desire to create the so-deferred Committee, at which point the Parties will thereafter promptly create the so-deferred Committee.

  

			
	 Committee
	  	 Purpose

	Joint Steering Committee (“JSC”)	  	Establish projects for the Bacteriophage Program and establish the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans (except for
decisions of the IPC). The JSC shall establish budgets not less than on a quarterly basis.
		
	Chemistry, Manufacturing and Controls Committee (“CMCC”)	  	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Bacteriophage Program.
		
	Regulatory Committee (“RC”)	  	Review and approve all research and development plans and projects, including clinical projects, associated with any necessary regulatory approvals, all associated publications, and
all regulatory filings and correspondence relating to gaining regulatory approval for new Ampliphi Products under the Bacteriophage Program; and review and approve itemized budgets with respect to the foregoing.
		
	Commercialization Committee (“CC”)	  	Establish project plans and review and approve activities and budgets for Commercialization activities under the Bacteriophage Program.

  
 8 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

			
	 Committee
	  	 Purpose

	Intellectual Property Committee (“IPC”)	  	Evaluate all intellectual property issues in connection with the Bacteriophage Program; review and approve itemized budgets with respect to the foregoing.

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives (not to exceed three
(3) for each Party) with appropriate expertise to serve as members of such Committee. For the JSC, the representatives must all be employees of such Party or an Affiliate of such Party. For Committees other than the JSC, the representatives
must all be employees of such Party or an Affiliate of such Party, with the caveat that each Party may designate for each such other Committee up to one (1) representative who is not an employee if : (i) such non-employee representative
agrees in writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party consents to the designation of such non-employee representative,
which consent shall not be unreasonably withheld. For purposes of this Section 2.3, employees of Third Security may, at Intrexon’s election, serve as members of a Committee as if they were employees of Intrexon. Each representative as
qualified above may serve on more than one (1) Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time upon written notice to the other Party, provided that any
replacement shall be qualified as set forth above. Each Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson
shall alternate between the Parties, with Ampliphi selecting the chairperson first for the JSC, RC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall be responsible for calling
meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 

(b) Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held
less frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to reactivate the
so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person or by means of telecommunication
(telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with Ampliphi selecting the first meeting location for each
Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee excepting that an

  
 9 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Intrexon employee or agent serving on a Committee shall not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of
providing manufacturing or support services as set forth in Sections 4.6 and 4.7 below. 
 (c) Meeting Agendas. Each
Party will disclose to the other proposed agenda items along with appropriate information at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other
Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a
specific agenda for such Committee meeting. 
 (d) Limitations of Committee Powers. Each Committee shall have only such
powers as are specifically delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no
Committee shall have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. 
 2.4 Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter within thirty (30) days of its initial consideration of such matter, then either Party
may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to
discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such dispute is not resolved by the Executive Officers within thirty
(30) days after submission of such dispute to such Executive Officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the authority to finally resolve such dispute acting in good faith.

 (a) Casting Vote at JSC. If a dispute at the JSC is not resolved pursuant to Section 2.4 above, then the
Executive Officer of Ampliphi shall have the authority to finally resolve such dispute. 
 (b) Casting Vote at CMCC. If a
dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i) in the case of any disputes relating to the Intrexon Materials, the manufacture of an Ampliphi Product through the use of Intrexon Channel Technology or Intrexon
IP, or the manufacturing of other components of Ampliphi Products contracted for or manufactured by Intrexon or reasonable controls regarding the dissemination of Intrexon Technology, Intrexon IP or Intrexon Materials, the Executive Officer of
Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of any other disputes, the Executive Officer of Ampliphi shall have the authority to finally resolve such dispute. 

  
 10 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) Casting Vote at RC. If a dispute at the RC is not resolved pursuant to
Section 2.4 above, then the Executive Officer of Ampliphi shall have the authority to finally resolve such dispute. 

(d) Casting Vote at CC. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive Officer of
Ampliphi shall have the authority to finally resolve such dispute. 
 (e) Casting Vote at IPC. If a dispute at the IPC is
not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the Parties with respect to Product-Specific Program
Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11). 
 (f) Other Committees. If any additional Committee or subcommittee other than those set forth in Section 2.2(b) is formed, then the Parties shall, at the time of such formation, agree on which
Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 
 (g)
Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this
Agreement; (ii) expands the obligations of the other Party under this Agreement; (iii) negates any consent rights or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute
involving the breach or alleged breach of this Agreement; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is
inconsistent with applicable law. 
 ARTICLE 3 
 LICENSE GRANTS 
 3.1 Licenses to Ampliphi.

 (a) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Ampliphi a license under the
Intrexon IP to research, develop, use, import, make, have made, sell, and offer for sale Ampliphi Products in the Field in the Territory. Such license shall be exclusive (even as to Intrexon) with respect to any development, selling, offering for
sale or other Commercialization of Ampliphi Products in the Field in the Territory, and shall be otherwise non-exclusive. 

(b) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Ampliphi a non-exclusive, royalty-free
license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of Ampliphi Products in the promotional materials, packaging, and labeling for Ampliphi Products, as provided under and in accordance with
Section 4.9. 

  
 11 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.2 Sublicensing. Except as provided in this Section 3.2, Ampliphi shall not
sublicense the rights granted under Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Ampliphi Products or use or
display the Intrexon Trademarks, in each case except with Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the foregoing, Ampliphi shall have a limited right to sublicense
under the circumstances described in Sections 3.2(a), 3.2(b) and 3.2(c). 
 (a) Ampliphi may transfer, to the extent
reasonably necessary and after providing Intrexon with reasonable advance notice thereof, Intrexon Materials that are or express Ampliphi Products to a Third Party contractor performing contract manufacturing, fill, and/or finish responsibilities
for Ampliphi Products, and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Ampliphi transfers any Intrexon Materials under this Section 3.2(a), Ampliphi will remain
obligated to ensure that the rights of Intrexon in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated by any such Third Party contractor. 

(b) Ampliphi may, with Intrexon’s written consent, which consent shall not be unreasonably withheld or delayed, sublicense
the rights granted under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate, or grant an Affiliate the right to display the Intrexon Trademarks. In the event that Intrexon consents to any such grant or transfer to
an Affiliate, Ampliphi shall remain responsible for, and be guarantor of, the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection with such performance (as though such
Affiliate were Ampliphi), including any payment obligations owed to Intrexon hereunder. 
 (c) Ampliphi may, upon
approval of the JSC and with Intrexon’s written consent, which consent shall not be unreasonably withheld or delayed, sublicense the rights granted under Section 3.1 to a Third-Party, or transfer the Intrexon Materials to a Third Party, in
each case who is providing services to Ampliphi in connection with Ampliphi’s exercise of rights under this Agreement, provided that such sublicense or use of Intrexon Materials shall be limited to those rights or uses necessary for such Third
Party to provide such services. In the event that Intrexon consents to any such grant or transfer to such a Third Party, Ampliphi shall remain responsible for the performance by any such Third Party and shall cause such Third Party to comply with
the provisions of this Agreement in connection with such performance (as though such Third Party were Ampliphi). 
 3.3
Limitation on Sublicensees. None of the enforcement rights under the Intrexon Patents that are granted to Ampliphi pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written
consent, which may be withheld in Intrexon’s sole discretion. 
 3.4 No Non-Permitted Use. Ampliphi hereby covenants
that it shall not, nor shall it permit any Affiliate or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly
permitted by this Agreement. 

  
 12 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.5 Exclusivity. Neither Intrexon nor its Affiliates shall make the Intrexon
Channel Technology or Intrexon Materials available to any Third Party for the purpose of developing or Commercializing products in the Field (except as set forth in Section 3.2), and neither Intrexon nor any Affiliate shall pursue (either by
itself or with a Third Party or Affiliate) the research, development or Commercialization of any product for purpose of commercial use or sale in the Field, outside of the Bacteriophage Program. Further, neither Ampliphi nor its Affiliates shall
pursue (either by itself or with a Third Party or Affiliate) outside of the Bacteriophage Program the research, development or Commercialization of any product for purpose of commercial use or sale in the Field. For clarity, the foregoing sentence
shall not restrict Ampliphi’s rights to research, develop or Commercialize any bacteriophage therapeutic product in which the only bacteriophages included in such therapeutic are developed, selected, or produced without the use of synthetic DNA
technology, including bacteriophages selected through screening libraries, evolutionary selection or other techniques that do not involve the direct manipulation of nucleic acid sequences. 

3.6 No Prohibition on Intrexon. Except as explicitly set forth in Sections 2.1(b), 3.1 and 3.5, nothing in this Agreement shall
prevent Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, Ampliphi
acknowledges that, except as set forth in Section 2.1(b) with respect to the Reserved Field, Intrexon has all rights, in Intrexon’s sole discretion, to use or make the Intrexon Materials, Intrexon Channel Technology (including any genetic
materials used in an Ampliphi Product), and Intrexon IP available to Third Party channel partners or collaborators for use in fields outside the Field. 
 3.7 Rights to Regulatory Data. Ampliphi shall own and control all regulatory trial data and regulatory filings relating to Commercialization of Ampliphi Products (except to the extent such become
Reverted Products). Ampliphi shall provide to Intrexon at Intrexon’s request full copies of all trial data and reports, regulatory filings, and communications from regulatory authorities that relate specifically and solely to Ampliphi Products.
To the extent that there exist any trial data and reports, regulatory filings, and communications from regulatory authorities owned by Ampliphi that relate both to Ampliphi Products and other products produced by Ampliphi outside the Field or
outside the Bacteriophage Program, upon Intrexon’s request Ampliphi shall provide to Intrexon copies of the portions of such data, reports, filings, and communications that relate to Ampliphi Products, provided any such materials shall be
Confidential Information of Ampliphi (except to the extent such become Reverted Products). Subject to its ongoing obligations of exclusivity under Section 3.5, Intrexon shall be permitted, directly or in conjunction with or through partners or
other channel collaborators, to reference this data, reports, filings, and communications relating to Ampliphi Products in regulatory filings made to obtain regulatory approval for products for use in fields outside the Field. Intrexon shall have
the right to use any such information in developing and Commercializing products outside the Field and to license any Third Parties to do so. Notwithstanding the provisions of this Section 3.7, Intrexon shall not, outside of the Bacteriophage
Program, utilize any Ampliphi trial data or reports in support of obtaining regulatory approval for a product for use in the Field. 

  
 13 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.8 Third Party Licenses. 

(a) [*****] shall obtain [*****] any licenses from Third Parties that are required in order to practice the Intrexon Channel
Technology in the Field where the licensed intellectual property is reasonably necessary for Intrexon to conduct genetic and cell engineering and related analytic activities under JSC established plans for the Bacteriophage Program (but specifically
excluding intellectual property directed to any specific target genes, methods of treatment or therapy, cell lines, active pharmaceutical ingredients, delivery or packaging methods or apparatuses, or processes or methods for commercially
manufacturing Ampliphi Products) (“Supplemental In-Licensed Third Party IP”). Other than with respect to Supplemental In-Licensed Third Party IP, [*****] shall be solely responsible for obtaining [*****] any licenses from Third
Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or import Ampliphi Products (“Complementary In-Licensed Third Party IP”). Supplemental In-Licensed Third
Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “In-Licensed Program IP”. 
 (b) In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party IP or Complementary In-Licensed Third Party IP, such Party shall so notify the
other Party, and the IPC shall discuss such In-Licensed Program IP and its applicability to the Ampliphi Products and to the Field. As provided above in Section 3.8(a), [*****] shall have the sole right and responsibility to pursue a license
under Supplemental In-Licensed Third Party IP, and [*****] hereby covenants that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any time, provided that [*****] may (but shall not be obligated to) obtain
such a license directly if the Third Party owner or licensee of such Supplemental In-Licensed Third Party IP brings an infringement action against [*****] or its Affiliates or threatens to bring such action (to the extent such threats would
reasonably be considered to subject the Third Party owner or licensee to declaratory judgment jurisdiction) and, after written notice to [*****] of such action, [*****] fails to obtain a license to such Supplemental In-Licensed Third Party IP using
Diligent Efforts within ninety (90) days after such notice. Following the IPC’s discussion of any Complementary In-Licensed Third Party IP, subject to Section 3.8(c), [*****] shall have the right to pursue a license under
Complementary In-Licensed Third Party IP [*****]. For the avoidance of doubt, [*****] may at any time obtain a license under Complementary In-Licensed Third Party IP outside the Field [*****] provided that if [*****] decides to seek to obtain
such a license, it shall use reasonable efforts to coordinate its licensing activities in this regard with [*****]. 
 (c)
[*****] shall provide the proposed terms of any license under Complementary In-Licensed Third Party IP and the final version of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and
discussion prior to signing, and shall consider [*****] comments thereto in good faith. To the extent that [*****] obtains a license under Supplemental In-Licensed Third Party IP, [*****] shall provide the final version of the definitive license
agreement for such Supplemental In-

  
 14 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Licensed Third Party IP to the IPC. If [*****] acquires rights under any In-Licensed Program IP outside the Field, it will do so on a non-exclusive basis unless it obtains the prior written
consent of [*****] for such license outside the Field to be exclusive. Notwithstanding the foregoing sentence, [*****] shall have the right to acquire exclusive rights to Supplemental In-Licensed Third Party IP outside the Field if (i) such
rights outside the Field are limited specifically to non-genetically modified bacteriophages and, (ii) [*****] provides [*****] with thirty days notice prior to execution of any such exclusive rights to Supplemental In-Licensed Third Party IP.
Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.8 shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity,
(i) any costs incurred by [*****] in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by [*****], and (ii) any costs incurred by [*****] in obtaining and maintaining licenses to
Complementary In-Licensed Third Party IP (and, to the limited extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by [*****]. 
 (d) For any Third Party license under which Ampliphi or its Affiliates obtain a license under Patents claiming inventions or know-how specific to or used or incorporated into the development,
manufacture, and/or Commercialization of Ampliphi Products, Ampliphi shall use commercially reasonable efforts to ensure that Ampliphi will have the ability, pursuant to Section 10.4(h), to assign such agreement to Intrexon or grant a
sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)). 
 (e) The licenses granted to
Ampliphi under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license
agreement, subject to the cost allocation set forth in Section 3.8(c), provided that Intrexon shall either provide unredacted copies of such upstream license agreements to Ampliphi or shall disclose in writing to Ampliphi all of such
terms and conditions that are applicable to Ampliphi. Ampliphi shall not be responsible for complying with any provisions of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Ampliphi as provided
in the preceding sentence. 
 (f) If either Party receives notice from a Third Party concerning activities of a Party
taken in conjunction with performance of obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the receiving
Party shall inform the other party thereof within five (5) business days. 
 3.9 Licenses to Intrexon. Subject to
the terms and conditions of this Agreement, Ampliphi hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by Ampliphi or its Affiliates, solely
to the extent necessary for Intrexon to conduct those responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any Intrexon subcontractors as permitted in accord with
Section 4.6 or as otherwise permitted to be used by Intrexon in conjunction with support services under Section 4.7 (subject to JSC research plan approval). 

  
 15 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 3.10 Restrictions Relating to Intrexon Materials. Ampliphi and its permitted
sublicensees shall use the Intrexon Materials solely for purposes of the Bacteriophage Program and not for any other purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector
assembly technology, Ampliphi shall not, and shall ensure that Ampliphi personnel and permitted sublicensees do not, except as otherwise permitted in this Agreement (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any
Third Party; (b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to reverse engineer or
sequence such Intrexon Materials.  
 ARTICLE 4 

OTHER RIGHTS AND OBLIGATIONS 

4.1 Development and Commercialization. Subject to Sections 4.6 and 4.7, Ampliphi shall be solely responsible for the development
and Commercialization of Ampliphi Products. Ampliphi shall be responsible for all costs incurred in connection with the Bacteriophage Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing
capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating
the Fully Loaded Cost of manufacturing an Ampliphi Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and
amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested
by the JSC for the development of an Ampliphi Product (which research costs shall be reimbursed by Ampliphi); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within clause
(a) of the previous sentence shall include the scale-up of Intrexon Materials for generating data for regulatory approval submissions and Commercialization of Ampliphi Products undertaken pursuant to Section 4.6, which shall be at
Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Ampliphi (with Intrexon’s consent). 

4.2 Transfer of Technology and Information. The JSC shall develop a plan and protocol for each project and timing for the transfer
of relevant data and materials between the Parties. 
 4.3 Information and Reporting. Ampliphi will keep Intrexon
informed about Ampliphi’s efforts to develop and Commercialize Ampliphi Products, including reasonable and accurate summaries of Ampliphi’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated),
including regulatory plans, marketing plans (as updated), 

  
 16 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
progress towards meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Ampliphi
Products, including initiation or completion of a regulatory trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, product safety event, receipt of
Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.7 above, Ampliphi shall also provide to Intrexon copies of all final regulatory trial protocols and reports, and regulatory
correspondence and filings generated by Ampliphi as soon as practical after they become available. Intrexon will keep Ampliphi informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Ampliphi
Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Bacteriophage Program with respect to the Intrexon Channel
Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Ampliphi and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at
least once every six (6) months while Ampliphi Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. 

4.4 Regulatory Matters. At all times after the Effective Date, Ampliphi shall own and maintain, at its own cost, all regulatory
filings and regulatory approvals for Ampliphi Products that Ampliphi is developing or Commercializing pursuant to this Agreement. As such, Ampliphi shall be responsible for reporting all adverse events related to such Ampliphi Products to the
appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon
Materials outside of the Field, Intrexon may request that Ampliphi and Intrexon establish and execute a separate safety data exchange agreement, which agreement will address and govern the timely exchange of safety information generated by Ampliphi,
Intrexon, and relevant third parties with respect to specific Intrexon Materials. 
 4.5 Diligence. 

(a) Ampliphi shall use, and shall require its sublicensees to use, Diligent Efforts to develop and Commercialize Ampliphi
Products. 
 (b) Without limiting the generality of the foregoing, Intrexon may, from time to time, notify Ampliphi that
it believes it has identified a Superior Therapy, and in such case Intrexon shall provide to Ampliphi its then-available information about such therapy and reasonable written support for its conclusion that the therapy constitutes a Superior
Therapy. Ampliphi shall have the following obligations with respect to such proposed Superior Therapy: (i) within sixty (60) days after such notification, Ampliphi shall prepare and deliver to the JSC for review and approval a development
plan detailing how Ampliphi will pursue the Superior Therapy (including a proposed budget), provided that if Amplphi reasonably requests supplemental information in support of the determination that the proposed Ampliphi Product is a Superior
Therapy, such period shall be extended to sixty (60) days after Ampliphi receives 

  
 17 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
such supplemental inforation; (ii) Ampliphi shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan by the JSC, Ampliphi shall use
Diligent Efforts to pursue the development of the Superior Therapy under the Bacteriophage Program in accordance with such development plan. If Ampliphi fails to comply with the foregoing obligations, or if Ampliphi unreasonably exercises its
casting vote at the JSC to either (x) prevent the approval of a development plan for a Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a
development plan that is insufficient in view of the nature and magnitude of the opportunity presented by the Superior Therapy, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject to the limitation set forth
therein). For clarity, any dispute arising under this 4.5, including any dispute as to whether a proposed project constitutes a Superior Therapy (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance
with Article 11. 
 (c) The activities of Ampliphi’s Affiliates and any permitted sublicensees shall be attributed
to Ampliphi for the purposes of evaluating Ampliphi’s fulfillment of the obligations set forth in this Section 4.5. 

4.6 Manufacturing. Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform any
manufacturing activities in connection with the Bacteriophage Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, Intrexon may request that
Ampliphi and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials.
Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on
terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials or bulk quantities of other components of Ampliphi Products, then Intrexon shall provide to Ampliphi or a contract manufacturer
selected by Ampliphi and approved by Intrexon all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials or bulk qualities of other components of Ampliphi Products for use in the Field and
(b) reasonably necessary to enable Ampliphi or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials or bulk quantities of other components of Ampliphi Products. The costs and expenses
incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to Ampliphi or its contract manufacturer shall not be further transferred to any Third Party, including any
sublicensee of Ampliphi, or any Ampliphi Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit Ampliphi to switch manufacturers. 

4.7 Support Services. The JSC will meet promptly following the Effective Date and establish a plan under which Intrexon will
provide support services to Ampliphi for the research and development of Ampliphi Products under the Bacteriophage Program, which initial 

  
 18 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
plan may be amended from time to time by the JSC. Ampliphi will compensate Intrexon for such support services with cash payments equal to Intrexon’s Fully Loaded Cost in connection with such
services. Additionally, from time to time, on an ongoing basis, Ampliphi shall request, or Intrexon may propose, that Intrexon perform certain additional support services with respect to researching and developing new Ampliphi Products or improving
the manufacturing or processing methods for any existing Ampliphi Products. To the extent that the Parties mutually agree that Intrexon should perform such additional services, the Parties shall negotiate in good faith the terms under which services
would be performed, it being understood that Intrexon would be compensated for such services by cash payments equal to Intrexon’s Fully Loaded Cost in connection with such services. 

4.8 Compliance with Law. Each Party shall comply, and shall ensure that its Affiliates, (sub)licensees and Third Party contractors
comply, with all applicable laws, regulations, and guidelines applicable to the Bacteriophage Program, including without limitation those relating to the transport, storage, and handling of Intrexon Materials and Ampliphi Products. 

4.9 Trademarks and Patent Marking. To the extent permitted by applicable law and regulations, Ampliphi shall ensure that the
packaging, promotional materials, and labeling for Ampliphi Products, as appropriate, shall carry the applicable Intrexon Trademark(s), subject to Ampliphi’s reasonable approval of the size, position, and location thereof. Consistent with the
U.S. patent laws, Ampliphi shall ensure that Ampliphi Products, or their respective packaging or accompanying literature as appropriate, bear applicable and appropriate patent markings for Intrexon Patent numbers. Ampliphi shall provide Intrexon
with copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in order to obtain Intrexon’s approval thereof. Ampliphi’s use of the Intrexon Trademarks and patent
markings shall be subject to prior review and approval of the IPC. Ampliphi acknowledges Intrexon’s sole ownership of the Intrexon Trademarks and agrees not to take any action inconsistent with such ownership. Ampliphi covenants that it shall
not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Ampliphi Product). From time to time during the Term, Intrexon shall have the right to obtain from Ampliphi samples of Ampliphi
Product sold by Ampliphi or its Affiliates or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, for the purpose of inspecting the quality of such Ampliphi Products, the use of the Intrexon
Trademarks, or the accuracy of the patent markings. In the event that Intrexon inspects under this Section 4.9, Intrexon shall notify the result of such inspection to Ampliphi in writing thereafter. Ampliphi shall comply with reasonable
policies provided by Intrexon from time-to-time to maintain the goodwill and value of the Intrexon Trademarks. 
 ARTICLE 5

 COMPENSATION 
 5.1 Technology Access Fee. In partial consideration for Ampliphi’s appointment as an exclusive channel collaborator in the Field and the other rights granted to Ampliphi

  
 19 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
hereunder, Ampliphi shall issue to Intrexon, as an access fee for commercial license rights to the Intrexon IP granted under Section 3.1, certain equity interests in Ampliphi (each, a
“Technology Access Fee”) in accordance with the terms and conditions of the Stock Issuance Agreement of even date herewith (collectively, the “Equity Agreement”). As set forth in the Equity Agreement, the Technology
Access Fee will be that number of shares of Ampliphi common stock having a value equaling $3,000,000 (the number of shares to be calculated according to the terms of the Equity Agreement), and such shares issuance will occur contemporaneously with
the execution of this Agreement and the Equity Agreement. Provided that all closing conditions for the Technology Access Fee Shares (as defined in the Equity Agreement) that are within the reasonable control of Intrexon have been satisfied or
waived, the issuance of the Technology Access Fee Shares (as set forth in the Equity Agreement) is a condition subsequent to the effectiveness of this Agreement.  
 5.2 Commercialization Milestones. Upon the attainment of certain milestone events by an Ampliphi Product (whether such attainment is achieved by Ampliphi, an Affiliate of Ampliphi, or sublicensee
of Ampliphi), Ampliphi has agreed to make certain milestone payments to Intrexon as generally set forth below in Sections 5.2(a) and 5.2(b), which payments (subject to the terms and conditions of the Equity Agreement) shall be either in cash or in
Ampliphi common stock at Ampliphi’s sole discretion. 
 (a) Clinical Milestone. Within thirty (30) days of the
achievement of the Phase II Milestone Event (as defined in the Equity Agreement), Ampliphi will pay to Intrexon, according to the timelines and procedures set forth in the Equity Agreement, one of the following: (i) [*****] in cash, or
(ii) the Phase II Milestone Shares (as defined in the Equity Agreement). 
 (b) Approval Milestone. Within thirty
(30) days of the achievement of the Approval Milestone Event (as defined in the Equity Agreement), Ampliphi will pay to Intrexon, according to the timelines and procedures set forth in the Equity Agreement, one of the following:
(i) [*****] in cash, or (ii) the Approval Milestone Shares (as defined in the Equity Agreement). 
 5.3 Equity
Agreement Controls. All issuances of equity interests to Intrexon shall be in accordance with the terms and conditions of the Equity Agreement, which Equity Agreement shall control to the extent they may conflict with Sections 5.1 or 5.2 of this
Agreement. 
 5.4 Royalties. 
 (a) No later than thirty (30) days after each calendar quarter in which there are positive Net Sales arising from the sale of any Ampliphi Product in the Field in the Territory, Ampliphi shall
pay to Intrexon on an Ampliphi Product-by-Ampliphi Product basis a [*****] royalty on the first fifty million dollars ($50M) of annual Net Sales (cumulative worldwide for all Ampliphi Products), an [*****] royalty on the portion of annual Net Sales
(cumulative worldwide for all Ampliphi Products) exceeding fifty million dollars ($50M) up to 

  
 20 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
and including one hundred million dollars ($100M) of annual Net Sales (cumulative worldwide for all Ampliphi Products), a [*****] royalty on the portion of annual Net Sales exceeding one
hundred million dollars ($100M) up to and including two-hundred million dollars ($200M) of annual Net Sales (cumulative worldwide for all Ampliphi Products), and a [*****] royalty on the portion of annual Net Sales exceeding two-hundred million
dollars ($200M) of annual Net Sales (cumulative worldwide for all Ampliphi Products). Commencing with the Effective Date, in the event that are negative Net Sales for a particular Ampliphi Product in any calendar quarter, neither Ampliphi nor
Intrexon shall owe any payments hereunder with respect to such Ampliphi Product. 
 (b) No later than thirty
(30) days after each calendar quarter in which Ampliphi or any Ampliphi Affiliate receives Sublicensing Revenue, Ampliphi shall pay to Intrexon [*****] of such Sublicensing Revenue. 

5.5 Method of Payment. Payments due to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a
bank in the United States designated in writing by Intrexon. All references to “dollars” or “$” herein shall refer to United States dollars. 
 5.6 Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar quarter during which Net Sales have been generated, during which Sublicensing Revenue has been
received, or during which a negative Net Sales has occurred, Ampliphi shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter: 

(a) gross sales of each Ampliphi Product on a country-by-country basis; 

(b) itemized calculation of Net Sales, showing all applicable deductions; 

(c) itemized calculation of any payment due under Section 5.4(b), including an identification of the Ampliphi Product
involved, the quantity so used, the prevailing market price being used by Ampliphi, and an indication of how Ampliphi determined such prevailing market price; 
 (d) itemized calculation of Sublicensing Revenue; 
 (e) the amount
of any negative Net Sales for the applicable calendar quarter; 
 (f) the amount of the payment (if any) due pursuant to
each of Sections 5.4(a) and 5.4(b); 
 (g) the amount of taxes, if any, withheld to comply with any applicable law; and

 (h) the exchange rates used in any of the foregoing calculations. 

  
 21 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 For three (3) years after each sale or other commercial use of Ampliphi Product, or after incurring
any component item Ampliphi incorporated into its calculation of Net Sales or Sublicensing Revenues, or otherwise impacting Ampliphi’s calculations with regard to payments made to Intrexon in accord with Section 5.4(a) or 5.4(b), Ampliphi
shall keep (and shall ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate records of such sales, commercial use, or component item in sufficient detail to confirm the accuracy of the payment calculations
hereunder. 
 5.7 Audits. 
 (a) Upon the written request of Intrexon, Ampliphi shall permit an independent certified public accounting firm of internationally recognized standing selected by Intrexon, and reasonably
acceptable to Ampliphi, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of Ampliphi and its Affiliates to verify the accuracy and timeliness of
the reports and payments made by Ampliphi under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of such request. The accounting firm shall disclose to
both Parties whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted more than once in
any calendar year. 
 (b) If such accounting firm concludes that additional amounts were owed during such period,
Ampliphi shall pay additional amounts, with interest from the date originally due as set forth in Section 5.9, within thirty (30) days of receipt of the accounting firm’s written report. If the amount of the underpayment is greater
than five percent (5%) of the total amount actually owed for the period audited, then Ampliphi shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall pay all costs of the audit. In the event of
overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s). 
 (c) Intrexon shall (i) treat all information that it receives under this Section 5.7 in accordance with the confidentiality provisions of Article 7 and (ii) cause its accounting firm
to enter into an acceptable confidentiality agreement with Ampliphi obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Intrexon to
enforce its rights under this Agreement. 
 5.8 Taxes. The Parties will cooperate in good faith to obtain the benefit of
any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. Ampliphi shall deduct or withhold from any payments any taxes that it is required by applicable law to deduct or
withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to Ampliphi or the appropriate governmental authority
(with the assistance of Ampliphi to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the 

  
 22 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
applicable rate of withholding or to relieve Ampliphi of its obligation to withhold tax, and Ampliphi shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the
case may be, provided that Ampliphi has received evidence of Intrexon’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the
payment is due. If, in accordance with the foregoing, Ampliphi withholds any amount, it shall make timely payment to the proper taxing authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days
following that latter payment. 
 5.9 Late Payments. Any amount owed by Ampliphi to Intrexon under this Agreement that is
not paid within the applicable time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law. 

ARTICLE 6 

INTELLECTUAL PROPERTY 
 6.1 Ownership. 
 (a) Subject to the license granted under
Section 3.1, all rights in the Intrexon IP shall remain with Intrexon. 
 (b) Ampliphi and/or Intrexon may solely or
jointly conceive, reduce to practice or develop discoveries, inventions, processes, techniques, and other technology, whether or not patentable, in the course of performing the Bacteriophage Program (collectively “Inventions”). Each
Party shall promptly provide the other Party with a detailed written description of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws. 

(c) Intrexon shall solely own all right, title and interest in all Inventions made with, using, or otherwise incorporating
Intrexon Channel Technology, together with all Patent rights and other intellectual property rights therein (the “Channel-Related Program IP”). Ampliphi hereby assigns all of its right, title and interest in and to the
Channel-Related Program IP to Intrexon. Ampliphi agrees to execute such documents and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof.

 (d) Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other
technology, whether or not patentable, that is conceived, reduced to practice or developed by Ampliphi solely or jointly through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of
this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and shall be included in the Channel-Related Program IP. 

  
 23 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (e) All Information regarding Channel-Related Program IP shall be Confidential
Information of Intrexon. Ampliphi shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Bacteriophage Program, pursuant to which such person shall grant all rights in the Inventions to
Ampliphi (so that Ampliphi may convey certain of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Bacteriophage Program. 

6.2 Patent Prosecution. 
 (a) Intrexon shall have the sole right, but not the obligation, to (i) conduct and control the filing, prosecution and maintenance of the Intrexon Patents, and (ii) conduct and control
the filing, prosecution, and maintenance of any applications for patent term extension and/or supplementary protection certificates that may be available as a result of the regulatory approval of any Ampliphi Product. At the reasonable request of
Intrexon, Ampliphi shall cooperate with Intrexon in connection with such filing, prosecution, and maintenance, at Intrexon’s expense. Under no circumstances shall Ampliphi (A) file, attempt to file, or assist anyone else in filing, or
attempting to file, any Patent application, either in the United States or elsewhere, that claims or uses or purports to claim or use or relies for support upon an Invention owned by Intrexon, or (B) use, attempt to use, or assist anyone else
in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the
Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or (C) without prior approval of the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension or
supplementary protection certificate, either in the United States or elsewhere, that relies upon the regulatory approval of an Ampliphi Product. 
 (b) Ampliphi shall have the sole right, but not the obligation, to conduct and control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by Ampliphi or its
Affiliates and not assigned to Intrexon under Section 6.1(c) (“Ampliphi Program Patents”). At the reasonable request of Ampliphi, Intrexon shall cooperate with Ampliphi in connection with such filing, prosecution, and
maintenance, at Ampliphi’s expense. 
 (c) As used in this Section, “Prosecuting Party” means
Intrexon in the case of Intrexon Patents and Ampliphi in the case of Ampliphi Program Patents. The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including in-house
patent counsel as well as outside patent counsel) for the prosecution of the Intrexon Patents and Ampliphi Program Patents, as applicable. The Prosecuting Party shall: 
 (i) regularly provide the other Party in advance with reasonable information relating to the Prosecuting Party’s prosecution of Patents hereunder, including by providing copies of substantive
communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings and correspondence that the 

  
 24 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
Prosecuting Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public, the Prosecuting Party may,
in lieu of directly providing copies of such information to such other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

(ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided,
however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may
have comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 
 (iii) consult with the non-Prosecuting Party before taking any action that would reasonably be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and Ampliphi
Program Patents, as applicable. 
 6.3 Infringement of Patents by Third Parties. 

(a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate
action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other
appropriate action. 
 (b) Notwithstanding the foregoing, Ampliphi shall have the first right, but not the obligation, to
take appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either by settlement
or lawsuit or other appropriate action. If Ampliphi exercises the foregoing right, Intrexon agrees to be named in any such action if required. If Ampliphi fails to take the appropriate steps to enforce Product-Specific Program Patents against any
Field Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the obligation), at its
own expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action. 
 (c) With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific Program Patents pursuant to Section 6.3(b) but can reasonably be abated
through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action: (i) enforce one or more of the applicable Intrexon Patent(s) in a
commercially reasonable manner against such Field Infringement, or (ii) [*****]. To the extent Ampliphi shall be entitled to a share of the Recovery a set forth in Section 6.3(f), Intrexon and Ampliphi shall bear the costs and expenses of
such enforcement equally. The determination of which Intrexon Patent(s) to 

  
 25 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with Ampliphi on such determination. For the avoidance of doubt, Intrexon has
no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement. 
 (d) In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with the enforcing Party with respect to the investigation and prosecution of any
alleged, threatened, or actual Infringement, at the enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and expenses will be shared equally in accordance with terms thereof). 

(e) Ampliphi shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights
or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably withheld. Intrexon shall not settle or otherwise compromise any action under
this Section 6.3 in a way that diminishes the rights or interests of Ampliphi in the Field or adversely affects any Intrexon Patent with respect to the Field without Ampliphi’s prior written consent, which consent shall not be unreasonably
withheld. 
 (f) Except as otherwise agreed to by the Parties in writing, any settlements, damages or other monetary
awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party controlling such action, and second, to the costs and expenses (if any) of the other Party
(to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field
Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by Ampliphi pursuant to Section 6.3(b), Ampliphi shall retain
one hundred percent (100%) of any Recovery, but such Recovery shall be shared with Intrexon as Net Sales. In any action initiated by Intrexon or Ampliphi pursuant to Section 6.3(c), the Parties shall share the Recovery equally, and such
Recovery shall not be deemed to constitute Sublicensing Revenue. 
 (g) Ampliphi shall promptly notify Intrexon in
writing of any suspected, alleged, threatened, or actual Infringement of which it becomes aware, and Intrexon shall promptly notify Ampliphi in writing of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware.

  
 26 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 ARTICLE 7 
 CONFIDENTIALITY 
 7.1 Confidentiality. Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for
in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information: 

(a) was already known to the receiving Party and can be demonstrated by written records, other than under an obligation of
confidentiality, at the time of disclosure by the other Party; 
 (b) was generally available to the public or otherwise
part of the public domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to the
public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such
information to others; or 
 (e) was independently discovered or developed by the receiving Party without the use of
Confidential Information belonging to the disclosing Party, as documented by the receiving Party’s written records. 
 The
foregoing non-use and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies as a trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years
thereafter, in all other cases. 
 7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either
Party may disclose the Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) complying with applicable laws or regulations or valid court orders, provided that the Party making such disclosure provides the other Party with reasonable prior written notice of such
request or demand for disclosure and makes a reasonable effort to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used
only for the purposes for which the law or regulation required, or for which the order was issued; 
 (b) to regulatory
authorities in order to seek or obtain approval to conduct regulatory trials, or to gain regulatory approval, of Ampliphi Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators, provided
that the Party making such disclosure (i) provides the other Party with reasonable opportunity to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential
Information and (ii) does not unreasonably reject any such suggestions; 

  
 27 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) disclosure to investors and potential investors, acquirers, or merger
candidates who agree to maintain the confidentiality of such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 

(d) disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such as CROs) who
agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and 
 (e) disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators who agree to be bound by obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Article 7. 
 7.3 Publicity; Publications. The Parties agree that the
public announcement of the execution of this Agreement shall be substantially in the form of a press release and/or the filing of a Form 8-K by Ampliphi, which shall be mutually agreed to by the Parties. Each Party will provide the other Party with
the opportunity to review and comment, prior to submission or presentation, on external reports, publications and presentations (e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer
to the Bacteriophage Program or programs that are approved by the JSC. For such reports, publications, and presentations, the disclosing Party will provide the other Party at least fifteen (15) calendar days for review of the proposed
submission or presentation. In the case of a Form 8-K filing, such shall be provided to Intrexon by Ampliphi as soon as practicable prior to filing. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty
(30) days for review of the report or manuscript. The presenting Party will act in good faith to incorporate the comments of the other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the
other Party to postpone such submissions or presentations if necessary to provide the other Party with sufficient time to prepare and file any related Patent applications before the submission or presentation occurs, as appropriate. 

7.4 Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party,
subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point
during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably
available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider
and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such
comments. 
 7.5 Proprietary Information and Operational Audits. 

  
 28 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (a) For the purpose of confirming compliance with the Field-limited licenses
granted in Article 3, the diligence obligations of Article 4, and the confidentiality obligations under Article 7, Ampliphi acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and
inspect Ampliphi’s facilities and (ii) inspect all data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days
written notice from Intrexon to Ampliphi. Ampliphi will make itself and the pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 

(b) For the purpose of confirming compliance with the diligence obligations of Section 4.5, and the confidentiality
obligations under Article 7, Intrexon acknowledges that Ampliphi authorized representative(s), during regular business hours may (i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work products relating to
this Agreement. Any examination or inspection hereunder shall require five (5) business days written notice from Ampliphi to Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a reasonable basis, to
Ampliphi for the aforementioned compliance review. 
 (c) In view of the Intrexon Confidential Information, Intrexon
Know-How, and Intrexon Materials transferred to Ampliphi hereunder, Intrexon from time-to-time, but no more than quarterly, may request that Ampliphi confirm the status of the Intrexon Materials at Ampliphi (i.e. how much used, how much shipped, to
whom and any unused amounts destroyed (by whom, when) as well as any amounts returned to Intrexon or destroyed). Within ten (10) business days of Ampliphi’s receipt of any such written request, Ampliphi shall provide the written report to
Intrexon. 
 7.6 Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an agreement with its other
licensees and channel partners or collaborators to enable Ampliphi to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval to conduct regulatory
trials, or to gain regulatory approval of, Ampliphi Products, in a manner consistent with the provisions of Section 7.2(b). 

ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Representations and Warranties of Ampliphi. Ampliphi hereby represents and warrants to Intrexon that, as of the Effective
Date: 
 (a) Corporate Power. Ampliphi is duly organized and validly existing under the laws of Washington and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due
Authorization. Ampliphi is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Ampliphi’s behalf has been duly authorized to do so by all requisite
corporate action. 

  
 29 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (c) Binding Agreement. This Agreement is a legal and valid obligation binding
upon Ampliphi and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject
to general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Ampliphi does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound. Ampliphi is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement.

 8.2 Representations and Warranties of Intrexon. Intrexon hereby represents and warrants to Ampliphi that, as of the
Effective Date: 
 (a) Corporate Power. Intrexon is duly organized and validly existing under the laws of Virginia and has
full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due
Authorization. Intrexon is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s behalf has been duly authorized to do so by all requisite
corporate action. 
 (c) Binding Agreement. This Agreement is a legal and valid obligation binding upon Intrexon and
enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity
principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

(d) Additional Intellectual Property Representations. 

(i) Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to Ampliphi with
respect to the Intrexon Patents under this Agreement; 
 (ii) The Intrexon Patents existing as of the Effective Date constitute
all of the Patents Controlled by Intrexon as of such date that are necessary for the development, manufacture and Commercialization of Ampliphi Products; 

  
 30 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (iii) Intrexon has not granted, and during the Term Intrexon will not grant, any right
or license, to any Third Party under the Intrexon IP that conflicts with the rights or licenses granted or to be granted to Ampliphi hereunder; 
 (iv) There is no pending litigation, and Intrexon has not received any written notice of any claims or litigation, seeking to invalidate or otherwise challenge the Intrexon Patents or Intrexon’s
rights therein; 
 (v) None of the Intrexon Patents is subject to any pending re-examination, opposition, interference or
litigation proceedings; 
 (vi) All of the Intrexon Patents have been filed and prosecuted in accordance with all applicable
laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 
 (vii) Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and development work, including development of Intrexon’s
products and technology providing Intrexon, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other
of such persons, during the period of employment or contract by Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to Ampliphi herein), and Intrexon is not aware
that any of its employees or consultants is in material violation thereof; 
 (viii) To Intrexon’s knowledge, there is no
infringement, misappropriation or violation by third parties of any Intrexon Channel Technology or Intrexon IP in the Field; 

(ix) There is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against Intrexon that
Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any written notice
of such claim; 
 (x) To Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving
a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer
(A) where the basis of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel
Technology in the Field; 
 (xi) None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon’s
knowledge, the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable 

  
 31 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
government agency, in whole or in part, and there is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any
such Intrexon Patents; and 
 (xii) Except as otherwise disclosed in writing to Ampliphi, Intrexon: (A) is in material
compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of
any product that is under development, manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other
correspondence or notice from the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any
Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which would, individually or in the
aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and Intrexon is not
in material violation of any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the
FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA
or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or proceeding; (2) has not received notice that the FDA or any
other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state,
local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or
were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement,
safety alert, post sale warning, letters to customers, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to Intrexon’s knowledge, no third party has
initiated, conducted or intends to initiate any such notice or action. 
 except, in each of (ix) through (xii), for any instances which
would not, individually or in the aggregate, result in a material adverse effect on the rights granted to Ampliphi hereunder or Intrexon’s ability to perform its obligations hereunder. 

  
 32 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 8.3 Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS
ARTICLE 8 OR IN THE EQUITY AGREEMENT, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF
THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 9 

INDEMNIFICATION 
 9.1 Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend Ampliphi and its Affiliates and their respective directors, officers, employees, and agents (collectively,
the “Ampliphi Indemnitees”) from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’ fees) (collectively, “Losses”) resulting from any
claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, “Claims”) to the extent arising from (a) the gross negligence or willful misconduct of Intrexon or any of its Affiliates, or their
respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than Ampliphi) or sublicensees; or (c) breach by Intrexon of any
representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to indemnify the Ampliphi Indemnitees to the extent that a Claim arises from (i) the gross negligence or willful
misconduct of Ampliphi or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a breach by Ampliphi of a representation, warranty, or covenant of this Agreement. 

9.2 Indemnification by Ampliphi. Ampliphi agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third
Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the
relevant upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims, to the extent arising from any of the following: (a) the gross negligence or willful misconduct
of Ampliphi or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials by or on behalf of Ampliphi or its Affiliates, licensees, or sublicensees; (c) breach by
Ampliphi of any material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport, distribution, sale or other disposition of any Ampliphi Product by
or on behalf of Ampliphi or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, Ampliphi shall not have any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the gross negligence
or willful misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of this Agreement. 

  
 33 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 9.3 Product Liability Claims. Notwithstanding the provisions of Section 9.2,
any Losses arising out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or Commercialization of any
Ampliphi Products for use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess Product Liability Costs”), shall be paid by
[*****], except to the extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ sublicensees, or any of the respective officers, directors,
employees and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement. 
 9.4 Control of Defense. As a condition precedent to any indemnification obligations hereunder, any entity entitled to indemnification under this Article 9 shall give written notice to the
indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If such Claim falls within the scope of the indemnification obligations of this Article 9, then the indemnifying Party shall assume the
defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall cooperate with the indemnifying Party in such defense. The indemnified Party may, at its option and expense, be represented by counsel
of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the indemnified Party without the indemnifying Party’s written consent, such
consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or (b) adversely
impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified Party otherwise agrees in writing. 
 9.5 Insurance. Immediately prior to, and during marketing of Ampliphi Products, Ampliphi shall maintain in effect and good standing a product liability insurance policy issued by a reputable
insurance company in amounts considered standard for the industry. Immediately prior to, and during the conduct of any regulatory trials, Ampliphi shall maintain in effect and good standing a regulatory trials liability insurance policy issued by a
reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, Ampliphi shall provide Intrexon with all details regarding such policies, including without limitation copies of the applicable
liability insurance contracts. Ampliphi shall use reasonable efforts to include Intrexon as an additional insured on any such policies. 
 ARTICLE 10 
 TERM; TERMINATION

 10.1 Term. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated
pursuant to Section 10.2 or 10.3 (the “Term”). 
 10.2 Termination for Material Breach; Termination
Under Section 4.5(b) 

  
 34 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (a) Either Party shall have the right to terminate this Agreement upon written
notice to the other Party if the other Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach; provided,
however, that if Ampliphi commits any breach of the provisions of Section 4.10 of this Agreement, Intrexon shall have the right to terminate this Agreement if Ampliphi fails after notice from Intrexon to cure such breach within thirty
(30) days following written notice thereof. 
 (b) Intrexon shall have the right to terminate this Agreement, at
its sole discretion, if any necessary shareholder, member, exchange, and/or board of director approvals of Ampliphi have not been obtained, and the Technology Access Fee Shares (as defined in the Equity Agreement) have not been issued, within the
time frames set forth in the Equity Agreement. 
 (c) Intrexon shall have the right to terminate this Agreement under
the circumstances set forth in Section 4.5(b) upon written notice to Ampliphi, such termination to become effective sixty (60) days following such written notice unless Ampliphi remedies the circumstances giving rise to such termination
within such sixty (60) day period. 
 (d) Intrexon shall have the right to terminate this Agreement should Ampliphi
execute any purported assignment of this Agreement contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to Ampliphi and becoming effective immediately upon such written notice.

 10.3 Termination by Ampliphi. Ampliphi shall have the right to voluntarily terminate this Agreement in its entirety
upon ninety (90) days written notice to Intrexon at any time. 
 10.4 Effect of Termination. In the event of
termination of this Agreement pursuant to Section 10.2 or Section 10.3, the following shall apply: 
 (a) Retained
Products. Ampliphi shall be permitted to continue the development and Commercialization in the Field of any product resulting from the Bacteriophage Program that, at the time of termination, satisfies at least one of the following criteria (a
“Retained Product”): 
 (i) the particular product is an Ampliphi Product that is being sold by Ampliphi (or,
as may be permitted under this Agreement, its Affiliates and, if applicable, (sub)licensees) triggering royalty payments therefor under Section 5.4(a) or (b) of this Agreement, 

(ii) the particular product is an Ampliphi Product that has received regulatory approval, 

(iii) the particular product is an Ampliphi Product that is the subject of an application for regulatory approval in the Field that is
pending before the applicable regulatory authority; 

  
 35 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (iv) the particular product is an Ampliphi Product that is the subject of an ongoing or
completed phase 2 or phase 3 clinical trial in the Field; or 
 (v) in the event of termination by Ampliphi pursuant to
Section 10.2, the particular product is an Ampliphi Product that is the subject of an effective investigational new drug application with the FDA, or is an Ampliphi Product for which Ampliphi has commenced at least one JSC-authorized in
vivo good laboratory practices animal study that is expected to be used for filing an investigational new drug application for such Ampliphi Product. 
 Such right to continue development and Commercialization shall be subject to Ampliphi’s full compliance with the payment provisions in Article 5, a continuing obligation for Ampliphi to use in accord
with Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and Commercialize any Retained Products, and all other provisions of this Agreement that survive termination. 
 (b) Termination of Licenses. Except as necessary for Ampliphi to continue to obtain regulatory approval for, develop, use, manufacture and Commercialize the Retained Products in the Field as
permitted by Section 10.4(a), all rights and licenses granted by Intrexon to Ampliphi under this Agreement shall terminate and shall revert to Intrexon without further action by either Intrexon or Ampliphi. Ampliphi’s license with respect
to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1. 
 (c) Reverted Products. All Ampliphi Products other than the Retained Products shall be referred to herein as the “Reverted Products.” Ampliphi shall immediately cease, and shall
cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and Ampliphi shall not use or practice, nor shall it cause or permit any of its Affiliates or, if
applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. Ampliphi shall immediately discontinue making any representation regarding its status as a licensee or channel collaborator
of Intrexon with respect to the Reverted Products. 
 (d) Intrexon Materials. Ampliphi shall promptly return, or at
Intrexon’s request, destroy, any Intrexon Materials in Ampliphi’s possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval, use, manufacture and
Commercialization of the Retained Products in the Field. 
 (e) Licenses to Intrexon. Ampliphi is automatically deemed to
grant to Intrexon a worldwide, fully paid, royalty-free, exclusive (even as to Ampliphi and its Affiliates), irrevocable, license (with full rights to sublicense) under the Ampliphi Termination IP, to make, have made, import, use, offer for sale and
sell Reverted Products and to use the Intrexon Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by Ampliphi in Reverted Products pursuant to Section 10.4(c). The Parties shall
also take such actions and execute such other instruments and documents as may be reasonably necessary to document such license to Intrexon. 

  
 36 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 (f) Regulatory Filings. Ampliphi shall promptly assign to Intrexon, and will
provide full copies of, all regulatory approvals and regulatory filings that relate specifically and solely to Reverted Products. Ampliphi shall also take such actions and execute such other instruments, assignments and documents as may be necessary
to effect the transfer of rights thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other products, Ampliphi shall provide copies of the portions of such
regulatory filings that relate to Reverted Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect to the Reverted Products. 

(g) Data Disclosure. Ampliphi shall provide to Intrexon copies of the relevant portions of all material reports and data,
including regulatory trial data and reports, obtained or generated by or on behalf of Ampliphi or its Affiliates to the extent that they relate to Reverted Products, within sixty (60) days of such termination unless otherwise agreed, and
Intrexon shall have the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so. 
 (h) Third Party Licenses. At Intrexon’s request, Ampliphi shall promptly provide to Intrexon copies of all Third Party agreements under which Ampliphi or its Affiliates obtained a license
under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or Commercialization of the Reverted Products. At Intrexon’s request such that Intrexon may Commercialize the Reverted
Products, Ampliphi shall promptly work with Intrexon to either, as appropriate (i) assign to Intrexon the Third Party agreement(s), or (ii) grant a sublicense (with an appropriate scope) to Intrexon under the Third Party agreement(s).
Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned Third Party agreements. Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations
associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify Ampliphi and Ampliphi shall not make such assignment or grant such sublicense (or cause it to be made or
granted). 
 (i) Remaining Materials. At the request of Intrexon, Ampliphi shall transfer to Intrexon all quantities of
Reverted Product (including final products or work-in-process) in the possession of Ampliphi or its Affiliates. Ampliphi shall transfer to Intrexon all such quantities of Reverted Products without charge, except that Intrexon shall pay the
reasonable costs of shipping. 
 (j) Third Party Vendors. At Intrexon’s request, Ampliphi shall promptly provide to
Intrexon copies of all agreements between Ampliphi or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or distribution of Reverted Products in the Territory. At Intrexon’s request, Ampliphi
shall promptly: (i) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting 

  
 37 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
assignment, immediately assign (or cause to be assigned), such agreements to Intrexon, and (ii) with respect to all other such Third Party agreements, Ampliphi shall reasonably cooperate to
assist Intrexon in obtaining the benefits of such agreements. Ampliphi shall be liable for any costs associated with assigning a Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such
costs are directly related to Ampliphi’s breach. For the avoidance of doubt, Intrexon shall have no obligation to assume any of Ampliphi’s obligations under any Third Party agreement. 

(k) Commercialization. Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more
Third Parties, and shall have the right, without obligation to Ampliphi, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate. 

(l) Confidential Information. Each Party shall promptly return, or at the other Party’s request destroy, any Confidential
Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each item of Confidential Information of the other Party
in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive copies on the recipient Party’s disaster
recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained Products (in the case of Ampliphi) or Reverted Products (in the case of
Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with this Section 10.4(l). 

10.5 Surviving Obligations. Termination or expiration of this Agreement shall not affect any rights of either Party arising out of
any event or occurrence prior to termination, including, without limitation, any obligation of Ampliphi to pay any amount which became due and payable under the terms and conditions of this Agreement prior to expiration or such termination. The
following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b)), 5.6 through 5.8, 6.1, 6.2 (with subsection (c) surviving only to the extent relating to
Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or Commercialized at such time, if any), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9, 11, and 12; and any relevant definitions in
Article 1. Further, Article 7 and Sections 4.5(a), 4.5(c), 5.2 through 5.9, and 9.5 will survive termination of this Agreement to the extent there are applicable Retained Products. 

ARTICLE 11 

DISPUTE RESOLUTION 
 11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and
without resort to litigation. In the event of any disputes, controversies or 

  
 38 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
differences which may arise between the Parties out of or in relation to or in connection with this Agreement, including, without limitation, any alleged failure to perform, or breach, of this
Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith
efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the provisions
of Section 11.2. 
 11.2 Arbitration. Any dispute, controversy, difference or claim which may arise between the
Parties, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach, performance, application or termination of this
Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the end of the thirty (30) day period referenced in
Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party, with the arbitration to be held in the state where the other Party’s principal office is located (or some other place as
may be mutually agreed by the Parties). Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator to resolve the issue, which arbitrator shall be neutral and independent of both
Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology industries, and shall have some experience in mediating or arbitrating
issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall select an arbitrator meeting the foregoing criteria and the two
(2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an arbitrator(s) is selected (in the case of the three-person panel,
when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the resolution for the matter at issue (the “Proposed
Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it may be amended at such time. Within fifteen (15) days
after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other Party’s Support Memorandum. Neither Party may have any other
communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 11.2; provided that, the arbitrator(s) may convene a hearing if the
arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days after the arbitrator’s appointment, the arbitrator(s) will select one of the
two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The decision of the arbitrator(s) shall be final, binding,
and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both Proposed Terms or award any other relief or take any other
action. 

  
 39 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 11.3 Governing Law. This Agreement shall be governed by and construed under the
substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

11.4 Award. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as set forth above under
Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the losing Party.
Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final
award in any United States District Court located in New York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach of
the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award
consequential, incidental, special, punitive or exemplary damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages. The only damages
recoverable under this Agreement are direct compensatory damages. 
 11.5 Costs. Each Party shall bear its own legal
fees. The arbitrator(s) shall assess his or her costs, fees and expenses against the Party losing the arbitration. 
 11.6
Injunctive Relief. Nothing in this Article 11 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or
other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that
a material breach by either Party of its obligations in Section 3.5 or Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies
otherwise available at law, including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.5 or Article 7, and without further proof of irreparable harm other
than this acknowledgement, such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically including, but not limited to, both interim and permanent restraining orders and injunctions, without bond, and
(b) such other and further equitable relief as the court may deem proper under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit a breaching Party’s opportunity to cure a material breach
as permitted in accordance with Section 10.2. 
 11.7 Confidentiality. The arbitration proceeding shall be
confidential and the arbitrator(s) shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with
respect to the proceedings or decision of the arbitrator(s) 

  
 40 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 
without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as
required in connection with the enforcement of such award or as otherwise required by applicable law. 
 11.8
Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason. 
 11.9 Jurisdiction. For the purposes of this Article 11, the Parties acknowledge their diversity and agree to accept the jurisdiction of any United States District Court located in New York for the
purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts.

 11.10 Patent Disputes. Notwithstanding any other provisions of this Article 11, and subject to the provisions of
Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall be submitted to a court of competent jurisdiction in the country in which such Patent was filed or
granted. 
 ARTICLE 12 
 GENERAL PROVISIONS 
 12.1 Use of Name.
No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trademark of the other in connection with the performance of this Agreement, except that (a) either
Party may use the name of the other Party as required by regulations and in press releases accompanying quarterly and annual earnings reports approved by the issuer’s Board of Directors, and (b) Ampliphi may use the Intrexon Trademarks in
accord with licenses and restrictions set forth herein. 
 12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO
THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS
PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 

12.3 Independent Parties. The Parties are not employees or legal representatives of the other Party for any purpose. Neither Party
shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business organization of any kind.

  
 41 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 12.4 Notice. All notices, including notices of address change, required or
permitted to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission
with the other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt
requested. All such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	If to Intrexon:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: President, Human Therapeutics Division
 Fax: (301) 556-9901

		
	with a copy to:	  	 Intrexon Corporation
 20358
Seneca Meadows Parkway
 Germantown, MD 20876
 Attention: Legal Department
 Fax: (301) 556-9902

		
	If to Ampliphi:	  	 Ampliphi Biosciences
 800 E.
Leigh St., Suite 54
 Richmond, VA 23219

Attention: Chief Executive Officer
 Fax:
                    

 12.5 Severability. In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 12.6 Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 

12.7 Entire Agreement; Amendment. This Agreement, including any exhibits attached hereto, constitute the entire, final, complete
and exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the Parties). All
information of Intrexon or Ampliphi to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth
in Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 

  
 42 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 12.8 Non-assignability; Binding on Successors. Any attempted assignment of the
rights or delegation of the obligations under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or delegate its obligations under
this Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or
substantially all of its assets, provided that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors,
executors, heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation,
corporate reorganization, or similar transaction, or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context
of a reverse triangular merger)), the intellectual property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement shall be automatically excluded from the rights licensed to the other Party under
this Agreement. 
 12.9 Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its
obligations under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation
earthquakes, governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property,
whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 
 12.11
Non-Solicitation. During the Term and for a period of one (1) year following the end of the Term, neither Ampliphi nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment
with, or hire any employee of the other Party or an individual who was employed by the other party within one (1) year prior to such solicitation, discussion, or hire, without the prior approval of such other Party. General employment
solicitations or advertisements shall not be considered direct or indirect solicitations, and are not prohibited under this Agreement. 
 12.12 Legal Compliance. The Parties shall review in good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 

  
 43 

 EXECUTION COPY 

CONFIDENTIAL 
 Portions
herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and
Exchange Commission. 
  

 12.13 Counterparts. This Agreement may be executed in any number of counterparts
(including by facsimile, PDF, or other means of electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart.

 [Remainder of page intentionally left blank.] 

  
 44 

 EXECUTION COPY 
 CONFIDENTIAL 
 IN WITNESS
WHEREOF, the Parties hereto have duly executed this Exclusive Channel Collaboration Agreement. 
  

							
	INTREXON CORPORATION	  	AMPLIPHI BIOSCIENCES CORPORATION
				
	 By:
	 	 /s/ Jayson Rieger
	  	 By:
	 	 /s/ Philip Young

							
				
	 Name:
	 	 Jayson M. Rieger, Ph.D.
	  	 Name:
	 	 Philip Young

				
	 Title:
	 	 President of Human Therapeutics Division and Senior Vice President
	  	 Title:
	 	 CEO

 SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

  
 45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]